Q-omics provides the consensus-scored TPTE2P5 profile across patient tissues and cancer cell-line models. TPTE2P5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TPTE2P5 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TPTE2P5 RNA expression shows 20,983 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, THCA, and LUAD as cancer lineages where TPTE2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPTE2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPTE2P5 survival associations across molecular data types. TPTE2P5 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPTE2P5 RNA expression–survival associations across cancer types. High TPTE2P5 expression shows unfavorable associations in UVM, but favorable associations in HNSC, BLCA, GBM, SARC and COAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for TPTE2P5 RNA expression.
This table summarizes TPTE2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TPTE2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPTE2P5 shows lower tumor expression in THCA, KIRC, KICH, KIRP, LUSC and BRCA. The THCA box plot shows higher TPTE2P5 RNA expression in normal versus tumor tissue (log2 FC = −1.078, t-test p < 0.001).
This table shows molecular features associated with TPTE2P5 in patient tissues and cancer cell lines. In patient samples, TPTE2P5 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
